Hallmarks of alternative splicing in cancer (original) (raw)

• Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ . Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40: 1413–1415.
  CAS PubMed Google Scholar
• Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470–476.
  Article CAS PubMed PubMed Central Google Scholar
• Venables JP . Aberrant and alternative splicing in cancer. Cancer Res 2004; 64: 7647–7654.
  CAS PubMed Google Scholar
• Ghigna C, Valacca C, Biamonti G . Alternative splicing and tumor progression. Curr Genomics 2008; 9: 556–570.
  CAS PubMed PubMed Central Google Scholar
• David CJ, Manley JL . Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 2010; 24: 2343–2364.
  CAS PubMed PubMed Central Google Scholar
• Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L et al. Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol 2009; 16: 670–676.
  CAS PubMed Google Scholar
• Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57–70.
  CAS PubMed Google Scholar
• Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
  CAS PubMed Google Scholar
• Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR . The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14: 185–193.
  CAS PubMed PubMed Central Google Scholar
• Zhang Z, Krainer AR . Involvement of SR proteins in mRNA surveillance. Mol Cell 2004; 16: 597–607.
  CAS PubMed Google Scholar
• Huang Y, Gattoni R, Stevenin J, Steitz JA . SR splicing factors serve as adapter proteins for TAP-dependent mRNA export. Mol Cell 2003; 11: 837–843.
  CAS PubMed Google Scholar
• Michlewski G, Sanford JR, Caceres JF . The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol Cell 2008; 30: 179–189.
  CAS PubMed Google Scholar
• Sanford JR, Gray NK, Beckmann K, Caceres JF . A novel role for shuttling SR proteins in mRNA translation. Genes Dev 2004; 18: 755–768.
  CAS PubMed PubMed Central Google Scholar
• Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H et al. The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 2011; 47: 422–433.
  CAS Google Scholar
• Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C et al. Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res 2010; 70: 3975–3984.
  CAS PubMed PubMed Central Google Scholar
• Anczukow O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 2012; 19: 220–228.
  CAS PubMed PubMed Central Google Scholar
• Shultz JC, Goehe RW, Murudkar CS, Wijesinghe DS, Mayton EK, Massiello A et al. SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Mol Cancer Res 2011; 9: 889–900.
  CAS PubMed PubMed Central Google Scholar
• Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 2011; 20: 768–780.
  CAS PubMed PubMed Central Google Scholar
• Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 2005; 20: 881–890.
  CAS PubMed Google Scholar
• Liu Y, Wu BQ, Zhong HH, Tian XX, Fang WG . Quantification of alternative splicing variants of human telomerase reverse transcriptase and correlations with telomerase activity in lung cancer. PLoS One 2012; 7: e38868.
  CAS PubMed PubMed Central Google Scholar
• Rha SY, Jeung HC, Park KH, Kim JJ, Chung HC . Changes of telomerase activity by alternative splicing of full-length and beta variants of hTERT in breast cancer patients. Oncol Res 2009; 18: 213–220.
  CAS PubMed Google Scholar
• Xu JH, Wang YC, Geng X, Li YY, Zhang WM . Changes of the alternative splicing variants of human telomerase reverse transcriptase during gastric carcinogenesis. Pathobiology 2009; 76: 23–29.
  CAS PubMed Google Scholar
• Amor S, Remy S, Dambrine G, Le Vern Y, Rasschaert D, Laurent S . Alternative splicing and nonsense-mediated decay regulate telomerase reverse transcriptase (TERT) expression during virus-induced lymphomagenesis in vivo. BMC Cancer 2010; 10: 571.
  CAS PubMed PubMed Central Google Scholar
• Wang H, Zhou M, Shi B, Zhang Q, Jiang H, Sun Y et al. Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 2011; 13: 461–471.
  CAS PubMed PubMed Central Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809–819.
  CAS PubMed PubMed Central Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387–390.
  CAS PubMed PubMed Central Google Scholar
• Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009; 219: 435–445.
  CAS PubMed Google Scholar
• Okumura N, Yoshida H, Kitagishi Y, Nishimura Y, Matsuda S . Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Biochem Biophys Res Commun 2011; 413: 395–399.
  CAS PubMed Google Scholar
• Fregoso OI, Das S, Akerman M, Krainer AR . Splicing-factor oncoprotein SRSF1 stabilizes p53 via RPL5 and induces cellular senescence. Mol Cell 2013; 50: 56–66.
  CAS PubMed PubMed Central Google Scholar
• Zhang K, Nowak I, Rushlow D, Gallie BL, Lohmann DR . Patterns of missplicing caused by RB1 gene mutations in patients with retinoblastoma and association with phenotypic expression. Hum Mutat 2008; 29: 475–484.
  CAS PubMed Google Scholar
• Lohmann DR . RB1 gene mutations in retinoblastoma. Hum Mutat 1999; 14: 283–288.
  CAS PubMed Google Scholar
• Cloutier P, Toutant J, Shkreta L, Goekjian S, Revil T, Chabot B . Antagonistic effects of the SRp30c protein and cryptic 5' splice sites on the alternative splicing of the apoptotic regulator Bcl-x. J Biol Chem 2008; 283: 21315–21324.
  CAS PubMed Google Scholar
• Reeve JG, Xiong J, Morgan J, Bleehen NM . Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer 1996; 73: 1193–1200.
  CAS PubMed PubMed Central Google Scholar
• Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567–1576.
  CAS PubMed PubMed Central Google Scholar
• Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC . Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996; 56: 2422–2427.
  CAS PubMed Google Scholar
• Shultz JC, Vu N, Shultz MD, Mba MU, Shapiro BA, Chalfant CE . The Proto-oncogene PKCiota regulates the alternative splicing of Bcl-x pre-mRNA. Mol Cancer Res 2012; 10: 660–669.
  CAS PubMed PubMed Central Google Scholar
• Bonnal S, Martinez C, Forch P, Bachi A, Wilm M, Valcarcel J . RBM5/Luca-15/H37 regulates Fas alternative splice site pairing after exon definition. Mol Cell 2008; 32: 81–95.
  CAS PubMed Google Scholar
• Himeji D, Horiuchi T, Tsukamoto H, Hayashi K, Watanabe T, Harada M . Characterization of caspase-8L: a novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. Blood 2002; 99: 4070–4078.
  CAS PubMed Google Scholar
• Pan D, Boon-Unge K, Govitrapong P, Zhou J . Emetine regulates the alternative splicing of caspase 9 in tumor cells. Oncol Lett 2011; 2: 1309–1312.
  CAS PubMed PubMed Central Google Scholar
• Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, Hawkins AJ, Shay JW et al. Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res 2010; 70: 9185–9196.
  CAS PubMed PubMed Central Google Scholar
• Merdzhanova G, Edmond V, De Seranno S, Van den Broeck A, Corcos L, Brambilla C et al. E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death Differ 2008; 15: 1815–1823.
  CAS PubMed Google Scholar
• Shkreta L, Froehlich U, Paquet ER, Toutant J, Elela SA, Chabot B . Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes. Mol Cancer Ther 2008; 7: 1398–1409.
  CAS PubMed Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342.
  CAS PubMed Google Scholar
• Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192–198.
  CAS PubMed Google Scholar
• Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N . Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031–26037.
  CAS PubMed Google Scholar
• Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 2010; 285: 5532–5540.
  CAS PubMed Google Scholar
• Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002; 62: 4123–4131.
  CAS PubMed Google Scholar
• Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI . Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 1996; 93: 1988–1992.
  CAS PubMed PubMed Central Google Scholar
• Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 1751.
  CAS PubMed PubMed Central Google Scholar
• Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 1993; 8: 925–931.
  CAS PubMed Google Scholar
• Ergorul C, Ray A, Huang W, Darland D, Luo ZK, Grosskreutz CL . Levels of vascular endothelial growth factor-A165b (VEGF-A165b are elevated in experimental glaucoma). Mol Vis 2008; 14: 1517–1524.
  CAS PubMed PubMed Central Google Scholar
• Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y et al. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol 2007; 18: 719–729.
  CAS PubMed Google Scholar
• Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C et al. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 2010; 29: 5392–5403.
  CAS PubMed Google Scholar
• Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64: 7822–7835.
  CAS PubMed Google Scholar
• Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S et al. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 2008; 98: 1366–1379.
  CAS PubMed PubMed Central Google Scholar
• Rennel E, Waine E, Guan H, Schuler Y, Leenders W, Woolard J et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 2008; 98: 1250–1257.
  CAS PubMed PubMed Central Google Scholar
• Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, Orlando A, Rigby H et al. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer 2007; 97: 223–230.
  CAS PubMed PubMed Central Google Scholar
• Peiris-Pages M, Harper SJ, Bates DO, Ramani P . Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth. J Pathol 2010; 222: 138–147.
  CAS PubMed PubMed Central Google Scholar
• Diaz R, Pena C, Silva J, Lorenzo Y, Garcia JM, Sanchez A et al. p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumours.VEGF165b downregulation as a marker for poor prognosis. Int J Cancer 2008; 123: 1060–1067.
  CAS PubMed Google Scholar
• Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 2008; 121 (Pt 20): 3487–3495.
  CAS PubMed Google Scholar
• Gammons MV, Federov O, Ivison D, Du C, Clark TL, Hopkins C et al. Topical anti-angiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative-AMD. Invest Ophthalmol Vis Sci 2013; 54: 6052–6062.
  CAS PubMed PubMed Central Google Scholar
• Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc Natl Acad Sci USA 2006; 103: 11329–11333.
  PubMed PubMed Central Google Scholar
• Keriel A, Mahuteau-Betzer F, Jacquet C, Plays M, Grierson D, Sitbon M et al. Protection against retrovirus pathogenesis by SR protein inhibitors. PLoS One 2009; 4: e4533.
  PubMed PubMed Central Google Scholar
• Kendall RL, Thomas KA . Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705–10709.
  CAS PubMed PubMed Central Google Scholar
• Boeckel JN, Guarani V, Koyanagi M, Roexe T, Lengeling A, Schermuly RT et al. Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1. Proc Natl Acad Sci USA 2011; 108: 3276–3281.
  CAS PubMed PubMed Central Google Scholar
• Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009; 15: 1023–1030.
  CAS PubMed PubMed Central Google Scholar
• Valastyan S, Weinberg RA . Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275–292.
  CAS PubMed PubMed Central Google Scholar
• Kalluri R, Weinberg RA . The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420–1428.
  CAS PubMed PubMed Central Google Scholar
• Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 2011; 7: e1002218.
  CAS PubMed PubMed Central Google Scholar
• Venables JP, Brosseau JP, Gadea G, Klinck R, Prinos P, Beaulieu JF et al. RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Mol Cell Biol 2013; 33: 396–405.
  CAS PubMed PubMed Central Google Scholar
• Warzecha CC, Jiang P, Amirikian K, Dittmar KA, Lu H, Shen S et al. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J 2010; 29: 3286–3300.
  CAS PubMed PubMed Central Google Scholar
• Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP . ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009; 33: 591–601.
  CAS PubMed PubMed Central Google Scholar
• Carstens RP, Wagner EJ, Garcia-Blanco MA . An intronic splicing silencer causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through involvement of polypyrimidine tract binding protein. Mol Cell Biol 2000; 20: 7388–7400.
  CAS PubMed PubMed Central Google Scholar
• Baraniak AP, Chen JR, Garcia-Blanco MA . Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice. Mol Cell Biol 2006; 26: 1209–1222.
  CAS PubMed PubMed Central Google Scholar
• Baraniak AP, Lasda EL, Wagner EJ, Garcia-Blanco MA . A stem structure in fibroblast growth factor receptor 2 transcripts mediates cell-type-specific splicing by approximating intronic control elements. Mol Cell Biol 2003; 23: 9327–9337.
  CAS PubMed PubMed Central Google Scholar
• Oltean S, Sorg BS, Albrecht T, Bonano VI, Brazas RM, Dewhirst MW et al. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci USA 2006; 103: 14116–14121.
  CAS PubMed PubMed Central Google Scholar
• Oltean S, Febbo PG, Garcia-Blanco MA . Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo. Clin Exp Metastasis 2008; 25: 611–619.
  CAS PubMed PubMed Central Google Scholar
• Reinke LM, Xu Y, Cheng C . Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition. J Biol Chem 2012; 287: 36435–36442.
  CAS PubMed PubMed Central Google Scholar
• Horiguchi K, Sakamoto K, Koinuma D, Semba K, Inoue A, Inoue S et al. TGF-beta drives epithelial-mesenchymal transition through deltaEF1-mediated downregulation of ESRP. Oncogene 2012; 31: 3190–3201.
  CAS PubMed Google Scholar
• Konrad L, Scheiber JA, Volck-Badouin E, Keilani MM, Laible L, Brandt H et al. Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells. BMC Genomics 2007; 8: 318.
  PubMed PubMed Central Google Scholar
• Warzecha CC, Carstens RP . Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol 2012; 22: 417–427.
  CAS PubMed PubMed Central Google Scholar
• Sharma S, Liao W, Zhou X, Wong DT, Lichtenstein A . Exon 11 skipping of E-cadherin RNA downregulates its expression in head and neck cancer cells. Mol Cancer Ther 2011; 10: 1751–1759.
  CAS PubMed PubMed Central Google Scholar
• Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064–1074.
  CAS PubMed PubMed Central Google Scholar
• Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005; 436: 123–127.
  CAS PubMed PubMed Central Google Scholar
• Warburg O. . On respiratory impairment in cancer cells. Science 1956; 124: 269–270.
  CAS PubMed Google Scholar
• Warburg O . On the origin of cancer cells. Science 1956; 123: 309–314.
  CAS PubMed Google Scholar
• David CJ, Chen M, Assanah M, Canoll P, Manley JL . HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463: 364–368.
  CAS PubMed Google Scholar
• Koslowski M, Tureci O, Bell C, Krause P, Lehr HA, Brunner J et al. Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Res 2002; 62: 6750–6755.
  CAS PubMed Google Scholar
• Rouas-Freiss N, Bruel S, Menier C, Marcou C, Moreau P, Carosella ED . Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis. Int J Cancer 2005; 117: 114–122.
  CAS PubMed Google Scholar
• Rodriguez-Cruz TG, Liu S, Khalili JS, Whittington M, Zhang M, Overwijk W et al. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity. PLoS One 2011; 6: e22939.
  CAS PubMed PubMed Central Google Scholar
• Goncalves V, Matos P, Jordan P . Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum Mol Genet 2009; 18: 3696–3707.
  CAS PubMed Google Scholar
• Thorsen K, Mansilla F, Schepeler T, Oster B, Rasmussen MH, Dyrskjot L et al. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol Cell Proteomics 2011; 10: M110 002998.
  PubMed Google Scholar
• Das S, Anczukow O, Akerman M, Krainer AR . Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep 2012; 1: 110–117.
  CAS PubMed PubMed Central Google Scholar
• Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 2008; 134: 1521–1531.
  CAS PubMed Google Scholar
• Cheng C, Yaffe MB, Sharp PA . A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 2006; 20: 1715–1720.
  CAS PubMed PubMed Central Google Scholar
• Bedford MT, Reed R, Leder P . WW domain-mediated interactions reveal a spliceosome-associated protein that binds a third class of proline-rich motif: the proline glycine and methionine-rich motif. Proc Natl Acad Sci USA 1998; 95: 10602–10607.
  CAS PubMed PubMed Central Google Scholar
• Woolard J, Vousden W, Moss SJ, Krishnakumar A, Gammons MV, Nowak DG et al. Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms. Chem Sci 2011; 2011: 273–278.
  PubMed Google Scholar